Takeda Pharmaceutical (TAK) Stock Price, News & Analysis

Company Overview

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Key Stats

• Today's Range: $13.30 to $13.42
• 50-Day Range: $13.29 to $14.93
• 52-Week Range: $12.57 to $15.08
• Volume: 1.56 million shs
• Average Volume: 1.80 million shs
• Market Capitalization: $42.57 billion
• P/E Ratio: 23.07
• Dividend Yield: 3.59%
• Price Target: N/A
• Consensus Rating: N/A

Takeda Pharmaceutical Stock Analysis - MarketRank™

Takeda Pharmaceutical scored higher than 74% of companies evaluated by MarketBeat, and ranked 294th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Takeda Pharmaceutical.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: -0.63%

Earnings Growth

Earnings for Takeda Pharmaceutical are expected to decrease by -0.63% in the coming year, from $1.58 to $1.57 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Takeda Pharmaceutical is 23.07, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.55.

Price to Earnings Ratio vs. Sector

The P/E ratio of Takeda Pharmaceutical is 23.07, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 105.14.

Price to Earnings Growth Ratio

Takeda Pharmaceutical has a PEG Ratio of 0.26. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Takeda Pharmaceutical has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.19% of the outstanding shares of Takeda Pharmaceutical have been sold short.

Short Interest Ratio / Days to Cover

Takeda Pharmaceutical has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Takeda Pharmaceutical has recently decreased by 17.40%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Leadership

Takeda Pharmaceutical is a leading dividend payer. It pays a dividend yield of 3.59%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Takeda Pharmaceutical does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Takeda Pharmaceutical is 81.03%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, Takeda Pharmaceutical will have a dividend payout ratio of 29.94% next year. This indicates that Takeda Pharmaceutical will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.19% of the outstanding shares of Takeda Pharmaceutical have been sold short.

Short Interest Ratio / Days to Cover

Takeda Pharmaceutical has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Takeda Pharmaceutical has recently decreased by 17.40%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.66

News Sentiment

Takeda Pharmaceutical has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Takeda Pharmaceutical this week, compared to 4 articles on an average week.

Search Interest

Only 2 people have searched for TAK on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added Takeda Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Takeda Pharmaceutical insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.04% of the stock of Takeda Pharmaceutical is held by insiders.

Percentage Held by Institutions

Only 9.17% of the stock of Takeda Pharmaceutical is held by institutions.

TAK Stock Analysis - Frequently Asked Questions

How have TAK shares performed this year?

Takeda Pharmaceutical's stock was trading at $14.27 on January 1st, 2024. Since then, TAK stock has decreased by 6.2% and is now trading at $13.38.
View the best growth stocks for 2024 here.

Does Takeda Pharmaceutical have any subsidiaries?

The following companies are subsidiaries of Takeda Pharmaceutical: PvP Biologics, Shire, TiGenix, ARIAD Pharmaceuticals, Inviragen, LigoCyte Pharmaceuticals, Intellikine, and others.

Who are Takeda Pharmaceutical's major shareholders?

Top institutional shareholders of Takeda Pharmaceutical include FMR LLC (0.09%), Van ECK Associates Corp (0.07%), Managed Asset Portfolios LLC (0.05%) and Natixis Advisors LLC (0.01%).
View institutional ownership trends.

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Takeda Pharmaceutical investors own include Johnson & Johnson (JNJ), Meta Platforms (META), Taiwan Semiconductor Manufacturing (TSM), JPMorgan Chase & Co. (JPM), Alibaba Group (BABA), NVIDIA (NVDA) and Pfizer (PFE).

Company Calendar

• Today: 11/22/2024
• Next Earnings (Estimated): 2/06/2025
• Fiscal Year End: 3/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:TAK
• CUSIP: N/A
• CIK: 1395064
• Web: www.takeda.com
• Phone: (166) 204-2111
• Fax: 813-3278-2268
• Employees: 49,281
• Year Founded: 1781

Profitability

• EPS (Most Recent Fiscal Year): $0.58
• Trailing P/E Ratio: 23.07
• Forward P/E Ratio: 8.47
• P/E Growth: 0.26
• Net Income: $994.06 million
• Net Margins: 6.49%
• Pretax Margin: 0.92%
• Return on Equity: 10.00%
• Return on Assets: 4.78%

Debt

• Debt-to-Equity Ratio: 0.64
• Current Ratio: 1.28
• Quick Ratio: 0.77

Sales & Book Value

• Annual Sales: $4.55 trillion
• Price / Sales: 0.01
• Cash Flow: $3.19 per share
• Price / Cash Flow: 4.20
• Book Value: $14.57 per share
• Price / Book: 0.92

Miscellaneous

• Outstanding Shares: 3,181,875,000
• Free Float: 3,180,602,000
• Market Cap: $42.57 billion
• Optionable: Optionable
• Beta: 0.54